GANX
Gain Therapeutics, Inc.Company with tickers: GANX
CIK
1819411
CUSIP
36269B105
Shares Outstanding
42,654,038
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $5,353,545 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | $2,763,340 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-5,353,545 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-5,608,732 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.13 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.13 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |